• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Aripiprazole-Related Psychotic Exacerbations
RESEARCH UPDATE

Aripiprazole-Related Psychotic Exacerbations

January 1, 2023
Brian Miller, MD, PhD, MPH.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

REVIEW OF: Ma C-H et al, Ther Adv Psychopharmacol 2022;12:1–10

STUDY TYPE: Randomized controlled trial

Aripiprazole has a unique mechanism of action. It is a partial agonist at the D2 receptor, and this has raised concerns that psychosis may worsen when switching to this drug from a full D2 antagonist. Observational studies of aripiprazole switches have also supported this idea, and this paper is the first controlled trial to examine aripiprazole-related exacerbations. 

This study reanalyzed an eight-week, open-label, randomized controlled trial of switching from other oral antipsychotics to aripiprazole. Seventy-nine adults (mean age 39) with schizophrenia/schizoaffective disorder were switched to aripiprazole 15 mg due to intolerable adverse effects or inadequate therapeutic effect of their current antipsychotic. Most were clinically stable with symptoms in the mild range (average PANSS score = 55). After two weeks of aripiprazole, subjects were randomized to taper their pre-switch antipsychotic over one (n = 38) or four (n = 41) weeks. Aripiprazole-related exacerbation was defined as an increase of ≥2 points on the four PANSS hallucination/delusion items within 28 days of starting aripiprazole.

Twenty-one (27%) subjects had an aripiprazole-related exacerbation and 46 (58%) did not. Most of the exacerbations (62%) occurred within the first week after switching. Compared to those who did not worsen with the switch, those who did had a higher baseline antipsychotic dose (406 vs 268 chlorpromazine equivalents) and were more likely to be taking first-generation antipsychotics (62% vs 35%). However, after controlling for age and sex, only the baseline antipsychotic dose remained a significant predictor of aripiprazole-related exacerbations.

Although the rates of aripiprazole-related exacerbations are high, we don’t know if this phenomenon is unique to aripiprazole because the study did not test switches to other antipsychotics. 

CARLAT TAKE

Watch for worsening of psychosis when switching to aripiprazole, particularly when the patient starts the cross-taper on high doses of an antipsychotic or first-generation antipsychotics.


Research Update
KEYWORDS antipsychotics aripiprazole psychosis schizophrenia
    Brian Miller, MD, PhD, MPH.

    Topiramate Improves Weight in Schizophrenia in South Asians

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Viibryd Goes Generic, But Is It Worth Prescribing?
    20 Years of The Carlat Report
    Aripiprazole-Related Psychotic Exacerbations
    Should We Use Two Antidepressants to Treat Unipolar Depression?
    DBT Skills May Reduce Polypharmacy in Borderline Personality Disorder
    Pimavanserin Improves Negative Symptoms of Schizophrenia
    CME Post-Test, Psychiatric Education, TCPR, January 2023
    DOWNLOAD NOW
    Featured Book
    • HospPsychiatry_Spiral_Binding_Sm.png

      Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

      This comprehensive guide is designed to be a valuable resource for professionals working in...
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.